Cheryl Gault - 08 Sep 2025 Form 4 Insider Report for Rapport Therapeutics, Inc. (RAPP)

Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol
RAPP
Transactions as of
08 Sep 2025
Net transactions value
-$182,650
Form type
4
Filing time
10 Sep 2025, 16:15:04 UTC
Previous filing
05 Mar 2025
Next filing
01 Dec 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gault Cheryl Chief Operating Officer RAPPORT THERAPEUTICS, INC., 99 HIGH STREET, SUITE 2100, BOSTON /s/ Troy Ignelzi, Attorney-in-Fact 10 Sep 2025 0001839046

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RAPP Common Stock Options Exercise $9,000 +5,000 +2.9% $1.80 176,928 08 Sep 2025 Direct F1
transaction RAPP Common Stock Sale $191,650 -5,000 -2.8% $38.33* 171,928 08 Sep 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RAPP Stock Option (Right to Buy) Options Exercise $0 -5,000 -4.3% $0.000000 110,407 08 Sep 2025 Common Stock 5,000 $1.80 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2024.
F2 25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.